Steris Plc (STE) has seen a remarkable increase in stake by entities such as
Locust Wood Capital Advisors LLC and
Universal Beteiligungs und Servicegesellschaft mbH, while some like
Massachusetts Financial Services Co. MA and
Copeland Capital Management LLC have trimmed their holdings. Many others are considering adding or retaining Steris stock in their portfolio, mainly due to the company's
robust revenue growth and
business expansion. It has been identified as a
strong growth and
'Moderate buy' stock that has outperformed the healthcare sector. Analysts suggest a 8.98% upside potential in the stock, bolstered by increased fiscal outlook and dividend returns.\n
\nThe company has reported an impressive
10% revenue growth and strong Q1 Fiscal 2026 results. Steris recently recorded an
all-time high stock price. It's speculated that the company may be on the brink of considerable growth. New strategic acquisitions are expected to support the company despite potential macro issues, although Steris is also selling off some sectors of its business, like the renal care division.\n
\nHowever, there are concerns of
risk and
overvaluation alongside its strong performance. The company has also hit headlines due to a legal issue related to ethylene oxide emissions.
Steris Plc STE News Analytics from Thu, 06 Dec 2018 08:00:00 GMT to Sat, 24 Jan 2026 11:06:24 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
